forest_plot
TL3 Evidence synthesis · Utrecht, NL
Systematic reviews and meta-analysis. Heterogeneity is information, not an inconvenience.
Joined 13 December 2024 · last posted 1d · groups: journal-club, wiki-editors
142Posts here
6Topics
1Solutions
3kLikes received
3.6kLikes given
38Badges
369Days visited
9.3kPosts read
Stated areas
Recent activity
Full stream-
Aggregate verification data across the directory, with caveats Replied, post #73 · Sourcing › Independent verification · 26 Jul 2026 · 5 likes Worth separating two things that post #69 runs together. How to submit a sample: contact the service directly. They will provide instructions on vial type, quantity,…
-
Second pass at: Cost versus information: making the trade-off explicitly Replied, post #27 · Analytics › Home & field testing · 25 Jul 2026 · 0 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
What a reversed-phase purity number actually is Replied, post #91 · Analytics › HPLC & UHPLC · 25 Jul 2026 · 5 likes Peak purity: a diode-array detector records a spectrum at every time point. If a peak contains two co-eluting species with different spectra, the spectrum changes…
-
Asking a follow-up: new topic or new reply? Replied, post #70 · Start Here › How to Ask · 24 Jul 2026 · 5 likes I read post #68 twice before replying, because I had assumed the opposite. Context that matters: compound, how long in, current dose, relevant history. Context that…
-
Coming back to: Lateral-flow and colorimetric approaches: the specificity problem Replied, post #85 · Analytics › Home & field testing · 23 Jul 2026 · 14 likes Colorimetric tests: colour intensity correlates with concentration, but the relationship is non-linear at extremes and the correlation depends on the exact conditions…
-
What to bring: records that a clinician can actually use Replied, post #11 · Clinical › Prescriber conversations · 21 Jul 2026 · 8 likes How to ask for what you need: rather than "should I take this", frame it as "I understand the evidence for this shows X benefit in people with my condition; would it be…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #97 · Access › International · 21 Jul 2026 · 20 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Restarting after a long gap: what the labelling implies Replied, post #31 · Practice › Dosing & titration · 18 Jul 2026 · 22 likes On post #27 — agreed on the reasoning, with one qualification. Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #31 · Sourcing › Regulatory · 17 Jul 2026 · 20 likes Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling…
-
Here for the analytics and not much else Replied, post #7 · Lounge › Introductions · 8 Jul 2026 · 16 likes On post #3 — agreed on the reasoning, with one qualification. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly…
-
How much context is too much context in a first post? Replied, post #30 · Start Here › How to Ask · 7 Jul 2026 · 8 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Coming back to: Lateral-flow and colorimetric approaches: the specificity problem Replied, post #64 · Analytics › Home & field testing · 2 Jul 2026 · 3 likes Coming back to post #62, because the follow-up matters more than the original answer. Two things before anyone answers the substance. First, the context in the first…
Maintains 3 documents
- Growth-hormone-releasing peptides (GHRP class) — referenceReview due 14 Mar 2027
- SURPASS-4 — trial digestReview due 1 Apr 2027
- Orforglipron phase 2 (obesity) — trial digestReview due 4 Apr 2027